Global Metformin-Pioglitazone Market 2023-2030

    In Stock

    Coming Soon 




    Pioglitazone/metformin, sold under the brand name Actoplus Met among others, is a fixed-dose combination anti-diabetic medication used to improve glycemic control in adults with type two diabetes.It contains pioglitazone, a thiazolidinedione, and metformin, a biguanide


    Pioglitazone is a member of the thiazolidinedione class, it decreases insulin resistance in the periphery and in the liver resulting in increased insulin dependent glucose disposal and decreased hepatic glucose output.


    Metformin is a member of the biguanide class, improves glucose tolerance in patients with type two diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.


    Pioglitazone/metformin is indicated as an adjunct to diet and exercise:[medical citation needed] To improve glycemic control in patients with type two diabetes, or For patients who are already treated with a separate combination of pioglitazone and metformin, For patients whose diabetes is not adequately controlled with metformin alone, or For patients who have initially responded to pioglitazone alone and require additional glycemic control.



    infographic: Metformin-Pioglitazone Market , Metformin-Pioglitazone Market Size, Metformin-Pioglitazone Market Trends, Metformin-Pioglitazone Market Forecast, Metformin-Pioglitazone Market Risks, Metformin-Pioglitazone Market Report, Metformin-Pioglitazone Market Share.


    The Global Metformin-Pioglitazone Market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.



    Granules Metformin-Pioglitazone METFORMIN+PIOGLITAZONE is a medicine that is used to treat Type 2 diabetes. Type 2 diabetes is a chronic or lifelong condition affecting how your body processes glucose.


    People with type 2 diabetes either do not produce enough insulin, or if at all the insulin is produced, it is unable to perform its function in the body (insulin resistance).


    Due to this, the blood glucose level increases and symptoms such as frequent urination, increased thirst and increased hunger start. It can lead to serious complications like skin infection, eye problems (retinopathy), nerve damage (neuropathy), diabetic foot (foot ulcer), kidney disease (nephropathy), high blood pressure, and even stroke.


    METFORMIN+PIOGLITAZONE contains Gliclazide, metformin and pioglitazone. Gliclazide is a ‘sulfonylurea’ that acts by increasing the insulin released by the pancreas. On the other hand, Metformin, which is a ‘biguanide’, acts by lowering the glucose production in the liver, delaying glucose absorption from the intestines and increasing the body’s response to insulin.


    Pioglitazone works by decreasing the amount of glucose released by the liver and improving the sensitivity of tissues of muscles and fats towards insulin effects.




    1. How many Metformin-Pioglitazone  are manufactured per annum globally? Who are the sub-component suppliers in different regions?
    2. Cost breakup of a Global Metformin-Pioglitazone  and key vendor selection criteria
    3. Where is the Metformin-Pioglitazone  manufactured? What is the average margin per unit?
    4. Market share of Global Metformin-Pioglitazone  market manufacturers and their upcoming products
    5. Cost advantage for OEMs who manufacture Global Metformin-Pioglitazone  in-house
    6. key predictions for next 5 years in Global Metformin-Pioglitazone  market
    7. Average B-2-B Metformin-Pioglitazone  market price in all segments
    8. Latest trends in Metformin-Pioglitazone  market, by every market segment
    9. The market size (both volume and value) of the Metformin-Pioglitazone  market in 2023-2030 and every year in between?
    10. Production breakup of Metformin-Pioglitazone  market, by suppliers and their OEM relationship


    Sl no Topic
    1 Market Segmentation
    2 Scope of the report
    3 Abbreviations
    4 Research Methodology
    5 Executive Summary
    6 Introduction
    7 Insights from Industry stakeholders
    8 Cost breakdown of Product by sub-components and average profit margin
    9 Disruptive innovation in the Industry
    10 Technology trends in the Industry
    11 Consumer trends in the industry
    12 Recent Production Milestones
    13 Component Manufacturing in US, EU and China
    14 COVID-19 impact on overall market
    15 COVID-19 impact on Production of components
    16 COVID-19 impact on Point of sale
    17 Market Segmentation, Dynamics and Forecast by Geography, 2023-2030
    18 Market Segmentation, Dynamics and Forecast by Product Type, 2023-2030
    19 Market Segmentation, Dynamics and Forecast by Application, 2023-2030
    20 Market Segmentation, Dynamics and Forecast by End use, 2023-2030
    21 Product installation rate by OEM, 2023
    22 Incline/Decline in Average B-2-B selling price in past 5 years
    23 Competition from substitute products
    24 Gross margin and average profitability of suppliers
    25 New product development in past 12 months
    26 M&A in past 12 months
    27 Growth strategy of leading players
    28 Market share of vendors, 2023
    29 Company Profiles
    30 Unmet needs and opportunity for new suppliers
    31 Conclusion
    32 Appendix
      Your Cart
      Your cart is emptyReturn to Shop